絞り込み

16532

広告

Phase Ib Study of High-dose Intermittent Afatinib in Patients With Advanced Solid Tumors.

著者 Camidge DR , Sequist LV , Jänne PA , Weickhardt AJ , Dowling ES , Alicea J , Fan J , Oxnard GR
Clin Lung Cancer.2018 May 05 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (24view , 0users)

Miscellaneous

The present phase Ib study assessed the maximum tolerated dose (MTD), safety, pharmacokinetics, and antitumor activity of high-dose intermittent (HDI) afatinib monotherapy for patients with advanced solid tumors. The planned focus was patients with epidermal growth factor receptor (EGFR) T790M non-small-cell lung cancer (NSCLC).
PMID: 29861396 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード